Regarding PD-L1 expression analysis, 85.8% (109/127) of the non-responder patients presented less than 1% of PD-L1 tumor and immune cells’ expression, whereas 31.3% (26/83) of the responder patients presented higher expression (>1%) of this protein with both TPS and CPS methods (p = 0.005). The gene discussed is CD274; the disease is neoplasm.